News and Updates

Scientists at the Scripps Research Institute have successfully reversed a rare genetic disorder with autologous adult stem cell therapy.

Fluidigm has announced the design of an "integrated fluidic circuit" chip for the culturing of stem cells.

The U.S. company Stem Cell Therapy International and the S. Korean company Histostem today announced the terms of a litigation settlement.

Osiris Therapeutics reports that its adult stem cell product, Prochymal, has performed well in a subset of patients in a clinical trial, the FDA calls the trial a "failure" because the FDA does not recognize patient subsets.